Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/25333
Title: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Authors: 
Mesh: 
Issue Date: 2016
Citation: Br. J. Cancer.2016 09;(115)7:789-96
Abstract: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma.
PMID: 27599039
URI: https://hdl.handle.net/20.500.12530/25333
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC5046215.pdf424.4 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.